Elafibranor + Mao Inhibitors Interaction
Majorinteraction on record
Description
Co-administration may increase risk of myopathy and muscle injury. CPK elevation and myalgia occurred in patients on ELAFIBRANOR monotherapy.
Mechanism
Mechanism not fully characterized; additive myopathy risk
Source: NLP:elafibranor